By November 2025, US 10 Methoxy Iminostilbene prices dipped slightly, sort of mirroring the overall market trend of steady demand and some challenges with logistics. The US market relies heavily on imports from Asia and Europe, and a few things worked in its favor last month - freight rates from the Trans -Pacific region came down, and the US dollar got a bit stronger, all of which helped ease the cost of getting goods into the country. But, even with those positives, the 25% import tax on Chinese pharma supplies kept prices up. Despite that, supply lines are still chugging along just fine, with Chinese & Indian manufacturers churning out normal amounts and feedstocks available without a hitch. Meanwhile US distribution centers have got enough stock on hand. As for demand in the pharmaceutical sector - particularly in areas like neurology where drugs like Oxcarbazepine & Eslicarbazepine acetate are super important - that has been ticking along with production needs in the immediate term. Formulators of generic drugs have been playing it safe with just-in-time purchasing. With no FDA approval hurdles or supply chain hiccups to worry about, some minor price movement was expected. As of early Dec, prices are forecast to go up due to year end ordering, higher shipping prices & feedstock costs all adding up.
